Charter Radiology Participates in New iDEAS Trial for Study of Amyloid PET Imaging in Alzheimer’s Disease
November is Alzheimer’s Disease Awareness Month and Charter Radiology is proud to have been selected again to participate in the New iDEAS (Imaging Dementia – Evidence for Amyloid Scanning) clinical trial. This groundbreaking, nationwide study is assessing the impact of amyloid PET brain scans on patient management and health outcomes, and how amyloid PET scans can guide physicians in diagnosing and treating individuals who have memory loss.
Charter Radiology was among the first imaging centers in the country to offer Amyloid Vizamyl PET/CT for the study of memory and cognitive impairment.
In 2021, Charter Radiology participated in the initial phase of the iDEAS study, which enrolled approximately 18,000 participants in the largest study to date. The New iDEAS study is enrolling an additional 7,000 participants.
Alzheimer’s disease is the most common form of dementia that causes problems with memory, thinking, and behavior accounting for 50 to 60% of all cases. A diagnostic biomarker may help physicians separate patients who have Alzheimer’s disease pathology from those who do not.
Who is Eligible to Participate in New iDEAS?
Study participants must be Medicare beneficiaries, with Medicare as their primary health insurance, be referred by a qualified dementia specialist/neurologist, and must fit the study’s inclusion criteria.
A total of 7,000 Medicare beneficiaries meeting the study’s eligibility criteria will be consented and enrolled over 30 months at sites throughout the United States. To ensure diversity, the study will enroll at least 2,000 Black/African American participants, at least 2,000 Latinx/Hispanic participants, and up to 3,000 additional participants from other racial and ethnic backgrounds.
[Source: https://www.ideas-study.org/About-Us/FAQ]
Watch: Amyloid Vizamyl PET/CT in Action
Beta Amyloid Vizamyl PET/CT in a patient with a history of mild cognitive impairment. Findings are consistent with a positive Vizamyl scan.
Beta Amyloid Vizamyl PET/CT in a patient with a suspicious history of Alzheimer’s disease. Findings are consistent with a positive Vizamyl scan.
Patient with a history of mild cognitive impairment and hallucinations presents for an Amyloid PET/CT for evaluation.
November is Lung Cancer Awareness Month – Have You Been Screened?
When it comes to successfully treating lung cancer, early detection is key. At Charter Radiology, we’re committed to detecting lung disease at its earliest and most treatable stage, offering patients low-dose CT lung screening.
Lung screening is a CT scan of the chest to find disease before the symptoms begin.
Charter Radiology offers the most advanced, low-dose CT imaging for lung screening, reducing radiation doses by 60 to 80%.
Charter Radiology Wishes You A Happy Thanksgiving!
All of us at Charter Radiology are grateful to be able to serve your imaging needs. Thank you for entrusting us with your care and the care of your patients. Wishing everyone a happy Thanksgiving filled with family, friends, and gratitude.
